Sancuso, a five-day patch that fights nausea from cancer chemotherapy, has won a federal approval in the United States. The patch is worn on the arm and delivers a widely used anti-nausea medicine, known as granisetron, through the skin, Galashiels, UK-based pharmaceutical company ProStrakan said.

Nausea is a common side effect of chemotherapy that many patients face. Some patients have to prematurely stop their cancer treatment because of severe nausea and vomiting. Sancuso blocks serotonin receptors and helps prevent nausea. The only side effect in the clinical trial of this patch was constipation.

Granisetron, delivered by injection or orally via tablets or solution, is sold under the brand name Kytril by Roche Pharmaceuticals. It is the first anti-nausea patch for chemotherapy patients that won approval by the U.S. Food and Drug Administration (FDA) on Sunday. ProStrakan is also seeking European approval for Sancuso.

The FDA approval will help the company to expand into the American market with analysts predicting peak sales of $100 million. It is expected to be available by the end of the year.